Symbols / PSNL

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• Personalis, Inc. (PSNL): A Bull Case Theory - Yahoo Finance Mon, 02 Feb 2026 08
• $PSNL stock is up 9% today. Here's what we see in our data. - Quiver Quantitative ue, 10 Feb 2026 08
• Precision oncology genomics firm Personalis heads to TD Cowen conference - Stock Titan ue, 17 Feb 2026 21
• Personalis, Inc. (PSNL) Stock Analysis: A Promising 14.46% Upside Potential Amid Strategic Collaboration - DirectorsTalk Interviews Fri, 16 Jan 2026 08
• Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results - Business Wire hu, 12 Feb 2026 21
• Personalis: A Growth Inflection Is Imminent, Hold - Seeking Alpha hu, 27 Nov 2025 08
• Blood test spots cancer progression 161 days before scans in study - Stock Titan Mon, 02 Feb 2026 08
• Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance ue, 04 Nov 2025 08
• Insider Purchase: 10% owner at $PSNL Buys 31,430 Shares - Quiver Quantitative Fri, 13 Feb 2026 08
• Medicare to cover blood test that flags returning lung cancer earlier - Stock Titan ue, 10 Feb 2026 08
• Personalis (PSNL) Faces Persistent Losses and High Valuation as Revenue Growth Outpaces Market - Yahoo Finance hu, 06 Nov 2025 08
• New blood test add-on spots cancer resistance mutations in real time - Stock Titan Mon, 12 Jan 2026 08
• $PSNL stock is up 13% today. Here's what we see in our data. - Quiver Quantitative hu, 22 Jan 2026 08
• $PSNL stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 05 Dec 2025 08
• $PSNL stock is up 8% today. Here's what we see in our data. - Quiver Quantitative hu, 16 Oct 2025 07

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 42026-02-13 View
• 42026-01-23 View
• 8-K2026-01-08 View
• 8-K2025-11-28 View
• 42025-11-28 View
• 8-K2025-11-25 View
• 8-K2025-11-10 View
• 42025-11-05 View
• 10-Q2025-11-04 View
• 8-K2025-11-04 View
• 8-K2025-08-22 View
• 8-K2025-08-05 View
• 10-Q2025-08-05 View
• 42025-07-30 View
• 42025-07-30 View